Microfluidic Models for Respiratory Disease and Drug Studies

Shrestha, Jesus

Microfluidic Models for Respiratory Disease and Drug Studies

Shrestha, Jesus

Permalink

Publication Type:: Thesis
Issue Date:: 2022

Embargoed

	Filename	Description	Size
	01front.pdf	contents and abstract	362.03 kB	Adobe PDF	View/Open
	02whole.pdf	thesis	40.73 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Embargoed
Open Access

This item is currently unavailable due to the publisher's embargo.

The embargo period expires on 30 Aug 2024

Full metadata record

Field	Value	Language
dc.contributor.author	Shrestha, Jesus
dc.date.accessioned	2023-02-03T00:32:21Z
dc.date.available	2023-02-03T00:32:21Z
dc.date.issued	2022
dc.identifier.uri	http://hdl.handle.net/10453/165873
dc.description	University of Technology Sydney. Faculty of Engineering and Information Technology.	en_US.UTF-8
dc.description.abstract	Respiratory diseases impose substantial socioeconomic burdens on individuals and societies worldwide. To address the growing global burden of respiratory diseases, rapid and efficient preclinical evaluation models are urgently required to expedite the development of safe and effective therapeutics and vaccines. Recently, microfluidic lung-on-a-chip models that can mimic the functional units of the lung by culturing specific cell types with different biophysical and biochemical microenvironments have been extensively investigated. They are micro-engineered cell culture microfluidic devices that reproduce the key physiological functions and dynamic responses by replicating the 3D lung microarchitecture, microenvironment, and tissue-tissue interactions, which are absent in conventional models. This thesis presents a simple optimized protocol to treat the surface of the 3D-printed molds to rapidly fabricate lung-on-a-chip models. Different 3D-printed microfluidic platforms to model continuous positive airway pressure on sleep apnea patients and the effects of inhaling different size particulate matter present in the bushfire smoke were developed to better understand the underlying pathophysiology have been developed. Thus, this thesis effectively developed microfluidic models of different respiratory diseases to improve the understanding of disease pathophysiology and facilitate toxicological studies, treatment modalities, and drug screening to foster patient care.	en_US.UTF-8
dc.format	Thesis (PhD)
dc.language.iso	en_US	en_US.UTF-8
dc.relation	https://opus.lib.uts.edu.au/bitstream/10453/165873/2/02whole.pdf
dc.rights	info:eu-repo/semantics/embargoedAccess
dc.rights	The author owns the copyright in this thesis including all reproduction and reuse rights for the work. The work may not be altered without the permission of the copyright owner. Attribution is essential when quoting or paraphrasing from this thesis.
dc.rights	© 2022 Jesus Shrestha
dc.rights	au.edu.uts.lib/ppc
dc.title	Microfluidic Models for Respiratory Disease and Drug Studies	en_US.UTF-8
dc.type	Thesis
utslib.copyright.status	embargoed	*
utslib.copyright.embargo	2024-08-30T00:00:00+1000

Abstract:

Respiratory diseases impose substantial socioeconomic burdens on individuals and societies worldwide. To address the growing global burden of respiratory diseases, rapid and efficient preclinical evaluation models are urgently required to expedite the development of safe and effective therapeutics and vaccines. Recently, microfluidic lung-on-a-chip models that can mimic the functional units of the lung by culturing specific cell types with different biophysical and biochemical microenvironments have been extensively investigated. They are micro-engineered cell culture microfluidic devices that reproduce the key physiological functions and dynamic responses by replicating the 3D lung microarchitecture, microenvironment, and tissue-tissue interactions, which are absent in conventional models. This thesis presents a simple optimized protocol to treat the surface of the 3D-printed molds to rapidly fabricate lung-on-a-chip models. Different 3D-printed microfluidic platforms to model continuous positive airway pressure on sleep apnea patients and the effects of inhaling different size particulate matter present in the bushfire smoke were developed to better understand the underlying pathophysiology have been developed. Thus, this thesis effectively developed microfluidic models of different respiratory diseases to improve the understanding of disease pathophysiology and facilitate toxicological studies, treatment modalities, and drug screening to foster patient care.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/165873